MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec for the Treatment of X-linked Retinitis Pigmentosa
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
Generation Uranium Defines Multiple High-Impact Drill Targets At Yath Project, Leveraging Proven Discovery Model In One of Canada's Hottest Uranium Districts
SAGA Metals Executes Title Transfer Agreement to Expand Wolverine Heavy Rare Earth Element Project in Labrador-Grab Sample Assays Included up to 21.6% TREO
Metalsource Mining Intersects 1.1kg/t AgEq over 3.1m, Continues Identifying Widespread Polymetallic Mineralization While Expanding the Dip Length of the System Approximately 260m from Surface
